Effect of combined testing of ceramides with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China:a prospective observational study by Yao, Kang et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
http://dx.doi.org/10.1136/bmjopen-2018-028211
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Yao, K., Wang, Y., Liu, X., Shen, C., Hu, W., Wang, Z., ... Ge, J. (2019). Effect of combined testing of ceramides
with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China:
a prospective observational study. BMJ Open, 9(7), e028211. https://doi.org/10.1136/bmjopen-2018-028211
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 09. Jul. 2020
For peer review only
The Effect of Combined Testing of Ceramides with High-
sensitive Troponin T on the Detection of Acute Coronary 
Syndrome in Patients with Chest Pain in China：a 
prospective observational study
Journal: BMJ Open
Manuscript ID bmjopen-2018-028211.R3
Article Type: Research
Date Submitted by the 
Author: 24-May-2019
Complete List of Authors: Yao, Kang; Shanghai Institute of Cardiovascular Diseases, Zhongshan 
Hospital, Fudan University, Department of Cardiology
Wang, Yanzhong; Kings College London, School of Population Health and 
Environmental Sciences
Liu, Xuebo; Tongji Hospital, Tongji University, Department of Cardiology
shen, chengxing; Shanghai Jiao Tong University Affiliated Sixth People’s 
Hospital, Department of Cardiology
Hu, Wei; Minhang Hospital, Fudan University, Department of Cardiology
Wang, Zhe; Shanghai Institute of Cardiovascular Diseases, Zhongshan 
Hospital, Fudan University, Department of Cardiology
Wu, Runda; Shanghai Institute of Cardiovascular Diseases, Zhongshan 
Hospital, Fudan University, Department of Cardiology
Tang, Xianglin; Shanghai Institute of Cardiovascular Diseases, 
Zhongshan Hospital, Fudan University, Department of Cardiology
Sun, Aijun; Shanghai Institute of Cardiovascular Diseases, Zhongshan 
Hospital, Fudan University, Department of Cardiology; Shanghai Institute 
of Biomedical Science, Fudan University
Zou, Yunzeng; Shanghai Institute of Cardiovascular Diseases, 
Zhongshan Hospital, Fudan University, Department of Cardiology
Qian, Juying; Shanghai Institute of Cardiovascular Diseases, Zhongshan 
Hospital, Fudan University, Department of Cardiology
Wu, Guangyu; Qlife Lab Co., Ltd.
Guo, Xin; Qlife Lab Co., Ltd.
Cheng, Xiaoliang; Qlife Lab Co., Ltd.
Ge, Junbo; Shanghai Institute of Cardiovascular Diseases, Zhongshan 
Hospital, Fudan University, Department of Cardiology
<b>Primary Subject 
Heading</b>: Cardiovascular medicine
Secondary Subject Heading: Diagnostics, Epidemiology
Keywords: Cardiac Epidemiology < CARDIOLOGY, Cardiology < INTERNAL MEDICINE, Lipid disorders < DIABETES & ENDOCRINOLOGY
 
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
For peer review only
Page 1 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
1
The Effect of Combined Testing of Ceramides with High-sensitive Troponin T on the 
Detection of Acute Coronary Syndrome in Patients with Chest Pain in China ： a 
prospective observational study
Authors: Kang Yao1*, MD; Yanzhong Wang2*, PhD; Xuebo Liu3, MD; Cheng-Xing Shen4, MD; Wei 
Hu5, MD; Zhe Wang1; Runda Wu1, MD; Xianglin Tang1, MD; Aijun Sun1,6, MD; Yunzeng Zou1, MD; 
Juying Qian1, MD; Guangyu Wu7, MD, PhD; Xin Guo7, MD; Xiaoliang Cheng7, PhD; Junbo Ge1, MD
* Drs Yao and Wang contributed equally.
1. Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, 
Fudan University, Shanghai, China
2. School of Population Health and Environmental Sciences, King’s College London, London, UK
3. Department of Cardiology, Tongji Hospital, Tongji University, Shanghai, China
4. Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 
Shanghai, China
5. Department of Cardiology, Minhang Hospital, Fudan University, Shanghai, China
6. Institute of Biomedical Science, Fudan University, Shanghai, China 
7. Qlife Lab Co., Ltd., 700 Yishan Road, Shanghai Putian Information Industrial Park, Shanghai, 
China
Corresponding author:
Prof. Junbo Ge, MD, FACC, FESC 
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
Zhongshan Hospital, Fudan University
Page 2 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
2
180 Fenglin Road, Shanghai, China. Postcode: 200032
Tel: 0086 (0)21 64041990-2152; Fax: 0086 (0)21 64437078 
Email: ge.junbo2@zs-hospital.sh.cn
Word count: 3420 (The word count excludes the title page, abstract, tables, acknowledgements, 
contributions and references.)
Page 3 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
3
Abstract 
Objective Ceramides are associated with coronary plaque vulnerability. We aim to investigate the 
potential diagnostic value of ceramides for Acute Coronary Syndrome (ACS) in Chinese patients with 
chest pain.
Design Prospective observational survey.
Setting Shanghai, China, 2016-7.
Participants 2773 patients with chest pain from four hospitals in Shanghai, China between August 
2016 and October 2017.
Main outcome measures Performance of metabolites model in detection of ACS cases including ST-
elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and 
unstable angina (UA).  
Results – Plasma levels of 12 ceramides molecules and corresponding ratios were compared between 
patients diagnosed with ACS and those without. Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) ratio, 
Cer(d18:1/14:0) and Cer(d18:1/22:0) were independent predictors of ACS after adjustment of 
traditional risk factors and high sensitive-cTnT. Receiver operating characteristic curve (ROC) analysis 
showed a significant improvement in detecting ACS in the multi-variable model with ceramides as 
compared to that without [0.865 (0.840-0.889) vs. 0.808 (0.776-0.841), P < 0.001].
Conclusion – Distinct plasma ceramides are independent diagnostic predictors of ACS among patients 
with chest pain. Ceramides together with high-sensitive troponin and traditional factors showed great 
potential in identifying ACS among patients with chest pain.
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Article Summary
Strengths and limitations of this study
 This is the first study with systematic demonstration of plasma levels of 12 ceramide molecules in 
2773 Chinese patients with chest pain.
 Performance of ceramides levels in diagnosing acute coronary syndrome was assessed and 
validated in multi-center clinical studies.
 The time of ceramides level elevation after ACS occurrence cannot be assessed in the study design.
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1. Introduction 
Acute Coronary Syndrome (ACS), which includes both myocardial infarction (MI) and unstable angina 
(UA), is estimated to affect 1.4 million people in the United States, and 2.5 million people in China per 
year.1 2 However, patients with acute chest pain suggestive of ACS present with a heterogeneous array 
of conditions, including both non-ischaemic and ischemic chest pain.3 Only 17% of these are finally 
diagnosed as ACS caused by atherosclerotic and ischaemic heart disease.3
The likelihood of ACS in patients with chest pain is estimated via the entire clinical picture, including 
symptoms and physical examination findings, disease history, electrocardiogram (ECG) changes, and 
biomarkers results. Among biomarkers, cardiac troponins play a central role in establishing a diagnosis 
and stratifying risk. Troponins are more specific and sensitive than the traditional cardiac enzymes such 
as creatine kinase (CK), its isoenzyme MB (CK-MB), and myoglobin.4 However, there has been an 
increasing recognition of other biomarkers recently.5 Considerable effort has been made to improve the 
multi-biomarker based evaluation and management of ACS. Altered lipid metabolism associated with 
inflammation and oxidative stress initiate the pathological changes, including the formation of lipid-
laden foam cells and the necrotic lipid core of unstable plaque.6 7 As many lipid types are essential in 
atherogenesis, they should be used for ACS prediction.6
Ceramides are a family of lipid molecules that are found in high concentrations within cell membranes 
and play a key role in a variety of physiology functions including apoptosis, cell growth, cell adhesion 
and plasma membrane integrity maintenance.8 All tissues can synthesize ceramides de novo from 
saturated fats and sphingosine.9 However, lesional low density lipoprotein (LDL) is known to be rich 
in ceramide in the atherosclerotic plaque, and it contains 10- to 50-fold-higher content of ceramide 
when compared with plasma LDL.10 An arterial-wall sphingomyelinase (SMase) hydrolyzes the 
sphingomyelin (SM) of retained LDL.10 Plasma ceramide (d18:1/16:0), is associated with the fraction 
of necrotic core tissue and lipid core burden in coronary atherosclerosis.11 Inflammatory cytokine tumor 
necrosis factor alpha was shown to induce the production of ceramide in vascular endothelial cells,12 13 
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via the activation of SMase, accompanied by reactive oxygen species production.14 High content of 
oxidized LDL (ox-LDL) in the plaque is capable of activating precursors to matrix metallopeptidase 2, 
propagating the signalling of the ceramide pathway by activation of SMase.15 These findings suggest 
abnormal regulation of ceramides might be related to plaque instability and triggering of ACS.
Previous clinical research found that circulating ceramides are elevated in patients with hypertension,16 
obesity,17 18 and type 2 diabetes mellitus.18 Ceramides ratio levels such as Cer(d18:1/16:0) / 
Cer(d18:1/24:0) ratio, Cer(d18:1/18:0) / Cer(d18:1/24:0) ratio, and Cer(d18:1/24:1) / Cer(d18:1/24:0) 
ratio were proposed as useful biomarkers for cardiovascular death (CV death) prediction, as assessed 
by three independent coronary artery disease (CAD) cohorts.19
Although several studies have shown plasma levels of specific ceramide molecules are correlated with 
diagnosis of patients with cardiac events, no studies to date has evaluated the role of these ceramide 
molecules in detecting ACS from patients with chest pain. In this study, we aim to assess the value of 
ceramides in detection of ACS in patients with chest pain and whether a combination of ceramides and 
troponin could improve the diagnostic power.
2. Methods
2.1. Study design and participants
This is a prospective observational study involving four University affiliated hospitals in Shanghai, 
China. A total of 2990 patients with chest pain were consecutively recruited in chest pain outpatient 
during Monday to Friday between August 2016 and October 2017, and 2773 patients were finally 
admitted to wards of cardiology after pre-screening by the exclusion criteria. Sample size calculation is 
shown in Supplementary File. Patients were eligible if they were aged ≥18 and ≤ 80 years, presented 
with signs and symptoms of chest pain and agreed to participate in this study. The exclusion criteria 
were pregnant women; organ transplant patients; patients suffering from bleeding disorders; patients 
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with neoplasms with a life expectancy <1 year; chronic kidney disease (eGFR＜60 mL/min/1.73m2) 
and patients with a clear non-cardiac chest pain. A flow chart describing the inclusion and exclusion 
process is shown as Figure 1.  Full study protocol is provided upon request to the corresponding author.
The study complies with the Declaration of Helsinki and was approved by the Ethics Committee of 
Zhongshan Hospital, the Ethics Committee of Tongji Hospital, the Ethics Committee of Shanghai Jiao 
Tong University Affiliated Sixth People’s Hospital, and the Ethics Committee of Minhang Hospital. 
Written informed consent was obtained from all participants. 
2.2. Clinical and laboratory data
Clinical history, physical examination findings and blood tests including renal and liver functions, C-
reactive protein (CRP), D-dimer and high-sensitive cTnT (Roche) levels, ECG, coronary angiogram 
and echocardiogram findings were recorded in all patients. Troponin levels were measured by 
electrochemiluminescence method using high sensitive-cTnT assay (Roche Diagnostics) on Roche 
Cobas e601. The coefficient of variation in the hs-cTnT assay is ≤10% at the cut-off value of 13 ng/L. 
The 99 percentile upper reference limit of hs-cTnT assay is 14 ng/L. Besides, the assay also has a limit 
of blank of 3 ng/L and a limit of detection of 5 ng/L, and the analytical range is 3-10000 ng/L. Regular 
blood lipid tests were conducted using standard methods. Specifically, total cholesterol (TC) was 
measured by enzymatic cholesterol method using cholesterol oxidase/peroxidase aminophenazone 
(COD-PAP) reagent while total triglyceride (TG) was measured by Glycerol-3-Phosphate 
oxidase/peroxidase anti-peroxidase method (GPO-PAP) method. Low-density lipoprotein cholesterol 
(LDL-C) and high-density lipoprotein cholesterol (HDL-C) were measured by homogenous PEG 
modification enzyme method. Other blood biomedical assay of apolipoprotein (AI, AII, B, and E), 
lipoprotein (a), and lipoprotein-associated phospholipase were performed by immune transmission 
turbidity method. Performers of the above tests were blinded to the diagnosis of diseases. The detection 
limit, analytical range, and reference interval or decision limit are summarized in Supplementary Table 
1.
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2.3. Diagnosis of ACS
The diagnosis of ACS including UA, Non-ST segment elevation myocardial infarction (NSTEMI), and 
ST-segment elevation myocardial infarction (STEMI) was made by two independent cardiologists by 
reviewing all patients’ notes, including symptoms, 12-lead ECG, and blood tests results according to 
the 2014 American Heart Association /American College of Cardiology guidelines and international 
definition of myocardial infarction version 3. Type 1 and type 2 MI were both included.20 21 The 
agreement level and kappa value between the 2 cardiologists were 0.99 and 0.98. The cases where the 
2 cardiologists disagreed were reviewed by a senior cardiologist. All the cardiologists were blinded to 
ceramide levels. Cardiac chest pain with persistent ECG findings of elevation in the ST segment indicate 
STEMI. Cardiac chest pain and elevations in troponins levels without ST elevation indicate NSTEMI. 
Those with presence of 1 or more of 3 principal ischemic symptoms ((1) rest angina (lasting >20 
minutes), (2) new-onset (<2 months previously) severe angina, and (3) a crescendo pattern of 
occurrence (increasing in intensity, duration, frequency, or any combination of these factors)) without 
elevations in cardiac troponins are defined as UA.5 Participants were diagnosed with ACS when there 
is evidence of UA, NSTEMI or STEMI.
2.4. Quantification of plasma ceramides
Potential ceramides were generated from previous untargeted and targeted ceramide profile studies.22 23 
Analyses of 12 plasma ceramides were performed using a Waters Xevo TQ-S mass spectrometer 
(Manchester, UK) equipped with Waters Acuity UPLC I-Class (Milford, MA, USA) in a hospital and 
Qlife lab collaborative laboratory based in Department of Cardiology. The mass spectrometry was 
operated in multiple-reaction monitoring (MRM) mode with ESI-positive ionization. The capillary 
voltage was set at 3.0 kV. and the source temperature was 120℃. The desolvation temperature and gas 
flow were 400℃ and 800L/h, respectively. The source offset was maintained at 60V.
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Blood samples for ceramides test were collected and centrifuged using ethylene diamine tetraacetic acid 
(EDTA) anticoagulation tube at admission. Plasma were immediately stored in -80℃ for future 
analysis. Ceramides test were taken immediately after samples of all patients were collected.  Before 
analysis, the samples were thawed at room temperature, then a volume of 800 μl of protein precipitation 
solution (isopropanol) that containing D7-Cer d18:1/16:0 (0.01 pmol/μl), D7-Cer d18:1/18:0 (0.005 
pmol/μl), D7-Cer d18:1/24:0 (0.015 pmol/μl) and D7-Cer d18:1/24:1 (0.015 pmol/μl) was pipetted into 
1.5 mL Eppendorff tube after addition of 50 μL of plasma sample. The mixture was thoroughly vortexed 
for 10 min followed by 5-min centrifugation at 14,000 rpm. Supernatant (70 μL) was collected for 
LC/MS/MS analysis. Ceramides ratios were calculated using Cer(d18:1/16:0), Cer(d18:1/18:0), 
Cer(d18:1/24:1(15Z)) and Cer(d18:1/24:0).23 Lab technicians who were in charge for ceramides test 
were blinded to disease diagnosis.
2.5. Statistical methods
Continuous variables are summarized as mean (standard deviation) or median (interquartile range) and 
categorical data as count (percentage). Student’s t-test, Mann-Whitney U, and Wilcoxon signed rank 
tests were used to test differences in continuous variables where appropriate, and Chi-squared test was 
used for proportions. Univariate logistic regression was used to analyse the association of each variable 
and binary outcome. Multivariable logistic regression analyses were undertaken to identify the 
demographic, clinical and laboratory factors associated with ACS in patients with chest pain after 
adjusting for potential confounders and the final models included variables significantly associated with 
ACS.
Training and validation cohorts were developed via a 10-fold cross-validation approach repeated 10 
times.24 The estimate of prediction error is almost unbiased under 10-fold cross-validation. Repeated 
10 times that minimizes the cross-validated error is then used to build the final model.25 26 The 
performance and discrimination ability of the five models were assessed using the area under the 
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receiver operating curve (AUROC) and net reclassification index (NRI). ROC curves and NRI values 
were compared among models in training and validation datasets. 
All tests were two-tailed, and P values less than 0.05 were considered statistically significant. Odds 
ratios (OR) with 95% confidence intervals (CIs) for the chosen clinical and laboratory variables in the 
logistic regression models and AUROC and NRI values with 95% CIs for different test datasets were 
calculated. Statistical analyses were done with statistical software R, version 3.4.3.
2.6.Patient and Public Involvement
This study was conducted without patient and public involvement. 
3. Results
3.1. Demographics, lipid profiles and laboratory findings of patients 
The demographics, clinical and lab findings of all participants are reported in Table 1. Serial troponin 
levels were measured at 0h-3h after admission in all recruited patients and all patients underwent 
echocardiography and coronary angiography. In 2773 patients with chest pain, 354 (12.8%) were 
diagnosed with ACS, among whom 116 (4.2%) were UA, 114 (4.1%) were NSTEMI, and 124 (4.5%) 
were STEMI. All 116 patients with UA had a significant stenosis on coronary angiography. Compared 
to those without ACS, patients with ACS are more likely to be men (73.44% vs 67.57%), to be current 
smokers (31.35% vs 21.62%), and to have hypertension (68.92% vs 62.00%). Lipid profiles and 
lipoproteins including TG, TC, LDL-C, ApoB, ApoE, Lipoprotein(a) (Lp(a)) were significantly 
elevated in patients diagnosed with ACS while HDL-C and apolipoprotein A1 (ApoA1) were 
significantly lower in ACS patients (all p<0.001, except for Lp(a), p=0.023). CRP and cardiac damage 
markers including hs-cTnT and N-terminal pro-brain natriuretic peptide (NTproBNP) levels were 
significantly higher in ACS patients (all p<0.001). Demographics, lipid profiles and laboratory findings 
of patients diagnosed with STEMI, NSTEMI and UA were also reported in Supplementary Table 2.
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3.2. Plasma ceramides levels in ACS patients
Table 2 presents the levels of twelve ceramides molecules in patients with and without ACS. The levels 
of 12 ceramide molecules (Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1(15Z)), 
Cer(d18:1/14:0), Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:0/16:0), Cer(d18:0/18:0), Cer(d18:0/24:0), 
Cer(d18:0/24:1(15Z)), Cer(d18:1/24:1)) were all significantly elevated in patients with ACS compared 
to those without (all p<0.001, except for Cer(d18:1/24:0), p=0.028) (Table 2). In addition, 3 ceramide 
ratios (Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0)) were also significantly increased in ACS patients with all p 
values less than 0.001. In patients diagnosed with UA and NSTEMI, levels of ceramides and ceramide 
ratios were also significantly high r compared to patients diagnosed with non-ACS (Supplementary 
Table 3).
3.3. Association between plasma ceramides and traditional and cardiac damage markers 
The associations between plasma ceramides with traditional ACS risk factors and cardiac markers for 
myocardial injury are shown in Supplementary Table 4. Most of the 12 ceramide molecules and 
ceramide ratios were moderately correlated with lipid profiles including TG, TC, LDL-C, ApoB and 
ApoE, while CRP was shown to be weakly correlated with ceramides. There was no significant 
correlation between ceramides and myocardial damage markers including hs-cTnT and NTproBNP. 
3.4. Clinical predictors and multi-variable models for ACS
Clinical predictors for ACS were identified in univariate logistic regression analysis and are shown in 
Table 3. Being male, having hypertension, and being current smoker were significantly associated with 
ACS (p<0.05). Besides, most of the lipid profile (TG, TC, HDL-C, LDL-C, ApoA1 and ApoB) were 
significantly associated with ACS (all p<0.001). Also, increased levels of hs-cTnT (OR and 95%CI: 
2.45 [2.23-2.70]), NTproBNP (1.73 [1.60-1.87]) and CRP (1.73 [1.58, 1.90]) were significantly 
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associated with ACS. Furthermore, all 12 ceramides levels and 3 ceramides ratios were significantly 
associated with ACS with all p<0.001 except Cer(d18:1/24:0) with p=0.025 (Table 3).
Multivariable logistic regression analyzing independently significant predictors of ACS are shown in 
Table 4. Model 1 included traditional risk factors such as hypertension, current smoker, CRP, LDL-C 
and NTproBNP (all p<0.001 except for hypertension p=0.033). Model 2 only included hs-cTnT (2.454 
[2.239-2.701], p<0.001). Model 3 included traditional risk factors and hs-cTnT. Current smoker, CRP, 
LDL-C, NTproBNP as well as hs-cTnT were independently significant in detecting patients with ACS. 
Model 4 included traditional risk factors and ceramides levels, with OR (95%CI) of 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0): 2.960 (2.156-4.072), Cer(d18:1/14:0): 1.439 (1.007-2.062) and 
Cer(d18:1/22:0): 2.079 (1.315-3.288). Model 5 included traditional risk factors, hs-cTnT (2.190, 
[1.939-2.485]) and ceramides levels (Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0): 4.455 [3.112-6.396], 
Cer(d18:1/14:0): 1.73 [1.166-2.605], and Cer(d18:1/22:0): 2.301 [1.371, 3.866], all p<0.01). Ceramides 
were shown to be independently associated with ACS after adjusting for traditional factors and hs-
cTnT.
3.5. Discrimination and reclassification of ACS with various multi-variable logistic regression 
models
As shown in Table 5, the model including traditional factors (hypertension, current smoker, LDL-C, 
CRP and NT-proBNP level) had an area under the curve (AUC) of 0.780 (0.750-0.811) in diagnosing 
ACS. AUC of hs-cTnT in predicting ACS was 0.800 (0.767-0.833). After combining traditional factors 
and hs-cTnT, the AUC became 0.808 (0.776-0.841) (Figure 2A). The AUC of model including 
traditional factors and ceramides was 0.811 (0.784-0.837). Notably, when combining traditional factors, 
hs-cTnT, and ceramides, the AUC of the model rose to 0.865 (0.840-0.889) (Figure 2B). We also 
compared discrimination and reclassification power of these models. Results showed that ceramides 
significantly improved the AUC of the model with traditional factors and hs-cTnT (0.865 [0.840-0.889] 
vs. 0.808[0.776-0.841], p<0.001). Net reclassification index (NRI) analyses also showed that the model 
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including traditional factors and hs-cTnT was significantly improved by the inclusion of ceramides 
(NRI=0.511 (0.388-0.635), p<0.001).
4. Discussion 
In this study of 2773 Chinese patients with chest pain from four hospitals in Shanghai, China, levels of 
12 ceramides were systematically evaluated together with that of traditional risk factors and high-
sensitive troponin. Ceramides and their ratios were shown to be independent predictors of ACS in 
patients with chest pain after adjustment for traditional risk factors (e.g., age, sex, body mass index 
(BMI), smoking status, and blood cholesterol) and cardiac damage biomarkers (i.e., high-sensitive 
troponin). The proposed model with ceramides showed substantial promise and improved value as a 
risk evaluation tool for ACS with improved performance on model discrimination and reclassification. 
With targeted liquid chromatography–mass spectrometry based lipidomic approach, we have 
successfully established the characteristics of cardiac risk-related ceramides from 2773 Chinese patients 
with chest pain and confirmed our hypothesis that plasma levels of ceramide subspecies correlate with 
atherosclerotic plaque instability and hence might be used as lipidomic markers for ACS. 
This is to our knowledge the first study with systematic demonstration of plasma levels of 12 ceramide 
molecules in a Chinese population. Also, the selection of two ceramides molecules and one ceramide 
ratio as potential biomarkers for ACS has not been reported before. Although our ceramides-based 
diagnostic model showed great potential in identifying ACS among patients with chest pain, its clinical 
utility especially regarding rule-in and rule-out strategies and performances still need to be further 
investigated and validated to make it fully applicable in clinical settings. We were also restricted for 
not measuring ceramides levels in a serial pattern and lacking information about the relationships 
between ceramides levels and time from the onset of ACS. The study was possibly also limited by a 
potential selection bias for patients with higher risk of ACS during recruitment process from admitted 
patients rather than patients in emergency departments. In addition, the results found in our study need 
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to be validated in independent external cohorts. An improvement in the test technique of ceramides, 
including standardization of test protocol and automated pretreatment of samples is also needed to fulfil 
the requirement of clinical practice.
Our findings of two ceramides molecules (Cer(d18:1/14:0), Cer(d18:1/22:0)) and one ceramide ratios 
(Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0)) as diagnostic biomarkers for ACS among patients with 
suspected symptoms have never been reported before. In addition, only relatively modest correlations 
between ceramides and lipid profiles including TG, TC, LDL-C, ApoB and ApoE were detected and 
there was no significant correlation between ceramides with hs-cTnT, NT-proBNP and CRP levels, 
suggesting that the diagnostic value of ceramides for ACS might be independent of the above laboratory 
variables. Moreover, AUROC of multi-variable models showed significant improvement of ceramides 
on traditional risk factors and high-sensitive troponin T. This result provides evidence that distinct 
ceramide species serve as independent predictors for the risk of ACS, in addition to conventional blood 
biomarkers such as HDL-C and CRP levels. Ceramides measurement in high-throughput quality-
controlled environments is straightforward.19 By setting up clinical laboratories equipped with robotized 
sample handling systems and mass spectrometry equipment, it would be feasible to identify patients 
with chest pain at high cardiovascular risk using our ceramides-based diagnostic model. 19
Previous clinical research found that elevated ceramide plasma concentrations are associated with 
coronary plaque vulnerability evaluated by intravascular ultrasound virtual histology and near-infrared 
spectroscopy.11 Untargeted lipidomic analyses have identified CAD risk-related ceramide molecules 
(Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1)) and their ratios with Cer(d18:1/24:0) as potential 
risk stratifiers for CAD patients.22 A previous study applying ceramides to the prediction of 
cardiovascular death from patients with CAD showed that ceramides, independent of other lipid 
markers and CRP, were significantly associated with CV death.19 In a recent study including 495 
participants with coronary angiography and followed up for 18 years, ceramides were not associated 
with CAD but were independently associated with major adverse cardiovascular events.23 A weighted 
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sum of ceramides including Cer22:0 and Cer24:1 was also reported to be associated with a 2.18-fold 
higher risk of cardiovascular disease, which was similar with our results.27 Recent studies showed 
targeted profiling of ceramides predicted short-term and long-term major adverse cardiac events 
(MACE).28 29 Moreover, a consistent increase in ceramide levels and overexpression of 3 enzymes in 
ceramide biosynthesis were found on rat ischemic myocardium, which is consistent with the elevated 
plasma levels of ceramides found in our cohort.29 Nevertheless, no study has identified the diagnostic 
value of ceramides in patients with chest pain, while we develop models with lipidomic markers for 
ACS with additional value upon conventional factors and troponin.
Currently, the standard process for the diagnostic assessment of ACS in patients with suspected 
symptoms relies on clinical evaluation and high-sensitive troponin tests.4 20 However, high-sensitive 
troponin assays identify a larger number of patients with elevated troponin results but without a final 
diagnosis of ACS, making interpretation of test results challenging.30 The adoption of highly sensitive 
assays for ACS detection should be accompanied by serial tests and implementation of algorithms, 
leading to a longer period of observation31. In the current settings of Chinese hospitals, self-paying 
patients with chest pain tend to be over-prescribed by cardiologists with invasive and expensive tests 
such as coronary angiography. Noteworthily, ceramides levels of patients with UA are higher than those 
without ACS, which indicates that ceramides may help in identifying patients with UA and higher risk 
of ACS from populations without significant elevation of cardiac troponins. Moreover, ceramides levels 
were higher in NSTEMI patients compared to non-ACS ones, indicating a possible role of ceramides in 
distinguishing between patients with elevated troponins caused by ACS or non-ACS conditions. 
Nevertheless, the potential roles of ceramides in clinical diagnosis of UA and NSTEMI need further 
independent investigation and validation.
In conclusion, we have identified ceramides as independent biomarkers associated with ACS and 
developed a ceramides-based model to evaluate ACS risk among patients with chest pain. The model 
showed good model discrimination and net reclassification improvement as compared to other models. 
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Our study characterises ceramides species in Chinese patients with chest pain and demonstrates that 
ceramides are of diagnostic value and have the potential for detecting ACS, in addition to currently used 
lipid markers and high-sensitive troponin. 
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Table 1. Demographics, clinical and lab findings of included patients in total cohort.
Variables Total cohort (n=2773) non-ACS (n=2419) ACS (n=354) P
Age (years) 63.5 (9.6) 63.4 (9.4) 63.8 (10.6) 0.515
Male, n (%) 1894 (68.3) 1634 (67.6) 260 (73.4) 0.031
Diabetes, n (%) 689 (24.8) 600 (24.8) 89 (25.1) 0.943
Hypertension, n (%) 1744 (62.9) 1500 (62.0) 244 (68.9) 0.014
Current Smoker, n (%) 634 (22.9) 523 (21.6) 111 (31.4) <0.001
TG (mmol/L) 1.46 (1.03-2.10) 1.43 (1.01-2.07) 1.61 (1.16-2.23) <0.001
TC (mmol/L) 3.78 (3.17-4.59) 3.74 (3.13-4.49) 4.28 (3.51-5.01) <0.001
HDL-C (mmol/L) 1.09 (0.90-1.30) 1.09 (0.91-1.31) 1.01 (0.88-1.23) <0.001
LDL-C (mmol/L) 1.93 (1.40-2.61) 1.88 (1.36-2.53) 2.42 (1.77-3.08) <0.001
ApoA1 (g/L) 1.32 (1.16-1.51) 1.33 (1.17-1.52) 1.24 (1.08-1.43) <0.001
ApoB (g/L) 0.73 (0.58-0.91) 0.72 (0.57-0.89) 0.84 (0.67-1.03) <0.001
ApoE (mg/L) 38.0 (30.0-47.0) 37.0 (30.0-46.4) 41.0 (32.0-51.0) <0.001
Lp(a) (mg/L) 125.0 (53.0-290.3) 123.0 (51.0-282.0) 152.0 (65.0-329.0) 0.023
NTproBNP (ng/L) 100.0 (44.7-268.1) 87.4 (42.3-220.3) 364.1 (113.4-1264.0) <0.001
CRP (mg/L) 1.7 (0.7-5.5) 1.5 (0.6-4.8) 5.4 (1.8-13.9) <0.001
hs-cTnT (ng/L) 9 (5-16) 8 (5-13) 71 (11-474) <0.001
Data are median (interquartile range) or count (percentage). 
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; 
ApoB, apolipoprotein B; ApoE, apolipoprotein E; LP(a), lipoprotein(a); NTproBNP, N-terminal pro-brain natriuretic peptide; CRP, C-reactive protein; hs-
cTnT, high-sensitivity cardiac troponin T.
P value for the difference between patients diagnosed as ACS and non-ACS. 
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Table 2. Plasma levels of ceramides molecules and ratios in total cohort and by ACS status.
Ceramides (μmol/L) Total cohort (n=2773) non-ACS (n=2419) ACS (n=354) P
Cer(d18:1/16:0) 0.203 (0.165-0.248) 0.198 (0.162-0.241) 0.237 (0.203-0.286) <0.001
Cer(d18:1/18:0) 0.051 (0.037-0.069) 0.049 (0.036-0.065) 0.068 (0.051-0.084) <0.001
Cer(d18:1/24:0) 2.065 (1.607-2.680) 2.053 (1.592-2.672) 2.164 (1.675-2.757) 0.028
Cer(d18:1/24:1(15Z)) 0.583 (0.448-0.767) 0.569 (0.436-0.739) 0.730 (0.557-0.950) <0.001
Cer(d18:1/14:0) 0.0027 (0.0020-0.0036) 0.0027(0.0020-0.0035) 0.0030 (0.0024-0.0040) <0.001
Cer(d18:1/20:0) 0.053 (0.040-0.067) 0.051 (0.039-0.065) 0.063 (0.051-0.078) <0.001
Cer(d18:1/22:0) 0.381 (0.300-0.490) 0.375 (0.294-0.480) 0.416 (0.336-0.540) <0.001
Cer(d18:0/16:0) 0.010 (0.007-0.014) 0.010 (0.007-0.013) 0.011 (0.008-0.015) <0.001
Cer(d18:0/18:0) 0.005 (0.003-0.008) 0.005 (0.003-0.007) 0.007 (0.004-0.011) <0.001
Cer(d18:0/24:0) 0.061 (0.042-0.086) 0.060 (0.042-0.086) 0.068 (0.048-0.094) <0.001
Cer(d18:0/24:1(15Z)) 0.029 (0.020-0.044) 0.028 (0.019-0.041) 0.040 (0.026-0.058) <0.001
Cer(d18:1/24:1) 0.262 (0.195-0.375) 0.258 (0.192-0.372) 0.298 (0.221-0.386) <0.001
Ceramides Ratio
Cer(d18:1/16:0)/Cer(d18:1/24:0) 0.096 (0.080-0.116) 0.095 (0.079-0.114) 0.107 (0.090-0.132) <0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0) 0.024 (0.019-0.032) 0.023 (0.018-0.031) 0.031 (0.023-0.039) <0.001
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) 0.269 (0.214-0.360) 0.261 (0.211-0.345) 0.321 (0.253-0.426) <0.001
Data are median (interquartile range). 
P value for the difference between patients diagnosed as ACS and non-ACS. 
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Table 3. Univariate logistic regression showing significant predictors of ACS in patients 
with chest pain.
Total Cohort (n=2773)
Variables
OR (95%CI) P
Age 1.00 (0.99-1.02) 0.476
Gender 1.33 (1.04-1.71) 0.027
Diabetes 1.02 (0.78-1.31) 0.890
Hypertension 1.36 (1.07-1.73) 0.012
Current Smoker 1.66 (1.29-2.11) <0.001
TG* 1.40 (1.15-1.70) <0.001
TC* 5.17 (3.30-8.15) <0.001
HDL-C* 0.44 (0.30-0.66) <0.001
LDL-C* 3.14 (2.37-4.17) <0.001
ApoA1* 0.17 (0.09-0.29) <0.001
ApoB* 2.83 (2.05-4.01) <0.001
ApoE* 0.93 (0.76-1.17) 0.534
Lp(a)* 1.10 (1.00-1.21) 0.055
NTproBNP* 1.73 (1.61-1.88) <0.001
CRP* 1.74 (1.59-1.90) <0.001
hs-cTnT* 2.45 (2.24-2.70) <0.001
Cer(d18:1/16:0)* 7.53 (5.11-11.17) <0.001
Cer(d18:1/18:0)* 4.67 (3.55-6.17) <0.001
Cer(d18:1/24:0)* 1.41 (1.05-1.90) 0.025
Cer(d18:1/24:1(15Z))* 5.09 (3.79-6.87) <0.001
Cer(d18:1/14:0)* 2.04 (1.59-2.62) <0.001
Cer(d18:1/20:0)* 4.55 (3.35-6.22) <0.001
Cer(d18:1/22:0)* 2.36 (1.75-3.18) <0.001
Cer(d18:0/16:0)* 2.02 (1.61-2.55) <0.001
Cer(d18:0/18:0)* 2.26 (1.92-2.66) <0.001
Cer(d18:0/24:0)* 1.49 (1.21-1.84) <0.001
Cer(d18:0/24:1(15Z))* 2.73 (2.24-3.33) <0.001
Cer(d18:1/24:1)* 1.57 (1.26-1.96) <0.001
Cer(d18:1/16:0)/Cer(d18:1/24:0)* 4.11 (2.87-5.89) <0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0)* 3.84 (2.93-5.05) <0.001
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0)* 2.63 (2.08-3.34) <0.001
Data are odds ratio (OR) (95%CI). *Log transformed before analysis.
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoE, 
apolipoprotein E; LP(a), lipoprotein(a); NTproBNP, N-terminal pro-brain natriuretic peptide; CRP, C-
reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; Cer, ceramides.
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Table 4. Multivariable logistic regression showing significant predictors of ACS in patients with chest pain after adjustment for conventional risk 
factors.  
Baseline variables Model 1 Model 2 Model 3 Model 4 Model 5
Hypertension 1.37 (1.03-1.83)* — 1.35 (0.98-1.87) 1.41 (1.06-1.90)* 1.40 (1.01-1.96)*
Current Smoker 1.93 (1.43-2.58)‡ — 1.52 (1.09-2.10)* 1.99 (1.47-2.69)‡ 1.58 (1.12-2.21)†
LDL-C§ 2.63 (1.91-3.64)‡ — 2.01 (1.42-2.87)‡ 2.13 (1.51-3.04)‡ 1.64 (1.12-2.41)*
CRP§ 1.40 (1.27-1.55)‡ — 1.20 (1.07-1.34)† 1.38 (1.25-1.53)‡ 1.16 (1.03-1.31)*
NTproBNP§ 1.63 (1.49-1.78)‡ — 1.16 (1.04-1.29)† 1.57 (1.44-1.72)‡ 1.07 (0.95-1.19)
hs-cTnT§ — 2.45 (2.24-2.70)‡ 2.02 (1.80-2.27)‡ — 2.19 (1.94-2.49)‡
Cer(d18:1/24:1(15Z))/Cer(d18:1/
24:0)§ — — — 2.96 (2.16-4.07)‡ 4.46 (3.11-6.40)‡
Cer(d18:1/14:0)§ — — — 1.44 (1.01-2.06)* 1.74 (1.17-2.61)†
Cer(d18:1/22:0)§ — — — 2.08 (1.32-3.29)† 2.30 (1.37-3.87)†
Data are odds ratio (OR) (95%CI). §Log transformed before analysis.
Model 1. Included traditional risk factors (Hypertension, current smoker, LDL-C, CRP and NTproBNP levels).
Model 2. Only Included hs-cTnT.
Model 3. Included traditional risk factors, and hs-cTnT.
Model 4. Included traditional risk factors, and ceramides.
Model 5. Included traditional risk factors, hs-cTnT and ceramides.
LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; NTproBNP, N-terminal pro-brain natriuretic peptide; hs-cTnT, high-sensitivity cardiac 
troponin T; Cer, ceramides.
* P<0.05.
† P<0.01.
‡ P<0.001. 
Page 24 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
24
Table 5. Discrimination and reclassification of ACS with various multivariable logistic regression models. 
*Traditional risk factors include hypertension, current smoker, LDL-C, CRP and NTproBNP levels. 
†Ceramides include Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0), Cer(d18:1/14:0) and Cer(d18:1/22:0).
LDL-C, CRP, NT-proBNP, hs-cTnT and ceramides levels are log transformed before analysis.
hs-cTnT, high-sensitivity cardiac troponin T; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; NT-proBNP, N-terminal pro-brain 
natriuretic peptide.
P values-AUC and P values-NRI are for the difference between old models and new models. Bold used to highlight those P values<0.05.
Old model New model AUC (95% CI) P Value-AUC NRI (95% CI) P Value-NRI
Traditional factors* - 0.78 (0.75-0.81) - - -
hs-cTnT - 0.80 (0.77-0.83) - - -
Traditional factors* +hs-cTnT 0.81 (0.78-0.84) 0.220 0.52 (0.40-0.64) <0.001
Traditional factors* +Ceramides† 0.81 (0.78-0.84) <0.001 0.35 (0.23-0.47) <0.001
Traditional factors* + hs-cTnT +Ceramides† 0.87 (0.84-0.89) <0.001 0.51 (0.39-0.64) <0.001
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Figure 1: Flow chart.
Figure 2: Receiver operating characteristic (ROC) curves of multi-variable models for the 
discrimination of ACS.
(A) Traditional risk factors (hypertension, current smoker, LDL-C, CRP and NT-proBNP) and high-sensitive 
troponin are included in the model. (B) Traditional risk factors (hypertension, current smoker, LDL-C, CRP 
and NT-proBNP), high-sensitive troponin, Cer(d18:1/14:0), Cer(d18:1/22:0) and 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) are included in the model.
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Figure 1: Flow chart. 
185x99mm (300 x 300 DPI) 
Page 27 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
 
Figure 2: Receiver operating characteristic (ROC) curves of multi-variable models for the discrimination of 
ACS. 
99x110mm (300 x 300 DPI) 
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Supplementary Table 1 Summary of method information of laboratory analytes. 
Analytes Detection limit Analytical Range Reference Interval 
or Decision Limit 
Imprecision Range 
(Coefficient of Variance, %) 
3 3-10000 <9.4 
0.1 0.1-10.0 <2.0 
0.1 0.1-20.7 <1.6 
0.08 0.08-3.12 <1.5 
0.10 0.10-14.2 <1.2 
0.002 0.002-2.50 <3.7 
0.003 0.003-2.50 <3.5 
2 2-120 <50 
hs-TnT (ng/L) 
TG (mmol/L) 
TC (mmol/L) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
ApoA1 (g/L) 
ApoB (g/L) 
ApoE (mg/L) 
Lp(a) (mg/L) 30 30-1200 <3.1 
NT-proBNP (ng/L) 5 5-35000
<30 
<2.26 
<5.2 
Male >1.45 
Female >1.68 
<3.34 
Male 1.10-1.70 
Female 1.20-1.90 
Male 0.80-1.55 
Female 0.75-1.50 
27-45
<300 
<125 <4.2 
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Supplementary Table 2 Demographics, clinical and lab findings of included patients.  
Parameters Non-ACS STEMI NSTEMI UA NSTE-ACS 
2419 (87.2) 124 (4.5) 114 (4.1) 116 (4.2) 230 (8.3) 
64.0 (58.0-70.0) 64.0 (55.8-72.0) 63.0 (58.8-71.0) 66.0 (57.0-72.0) 64.0 (58.0-72.0) 
1634 (68) 98 (82) 89 (79) 66 (58) 155 (69) 
600 (25) 33 (28) 23 (21) 29 (25) 52 (23) 
1500 (62) 77 (64) 83 (74) 76 (67) 159 (70) 
523 (22) 46 (38) 47 (42) 18 (16) 65 (29) 
1.43 (1.01-2.08) 1.57 (1.15-2.16) 1.60 (1.12-2.04)∆∆ 1.75 (1.25-2.60)*** 1.68 (1.21-2.28) ## 
3.74 (3.13-4.49) 4.20 (3.55-4.99)§§ 4.28 (3.53-5.25)∆∆∆ 4.34 (3.47-5.01)*** 4.32 (3.51-5.04) ### 
1.090 (0.910-1.310) 0.990 (0.840-1.210)§ 0.980 (0.875-1.188)∆ 1.030 (0.905-1.240) 1.010 (0.885-1.230) # 
1.88 (1.36-2.53) 2.36 (1.79-3.12)§§§ 2.55 (1.82-3.06)∆∆∆ 2.23 (1.67-3.03)*** 2.47 (1.77-3.05) ### 
1.33 (1.17-1.52) 1.19 (1.06-1.38)§§§ 1.25 (1.09-1.43)∆ 1.27 (1.13-1.48) 1.25 (1.10-1.46) # 
0.720 (0.570-0.890) 0.815 (0.668-0.992)§ 0.915 (0.730-1.062)∆∆∆ 0.810 (0.650-1.000)** 0.870 (0.670-1.045) ### 
37.00 (30.00-46.37) 42.00 (34.50-47.25) 42.00 (34.00-51.25) 40.13 (28.00-53.00) 41.00 (31.15-52.00) 
123 (51.00-282.00) 162 (60.50-320.25) 183 (100.75-366.00) 96 (47.00-277.00) 148 (66.00-344.00) 
87.40  
(42.33-220.28) 
728.20 
 (259.90-1717.50)§§§ 
655.50 
 (171.70-1943.00)∆∆∆ 
105.90  
(52.50-215.30) 
198.15 
 (88.35-888.25) ### 
1.500 (0.600-4.800) 8.900 (2.650-20.950)§§§ 7.200 (3.100-17.600)∆∆∆ 2.50 (1.00-5.40) 4.55 (1.40-10.20) ### 
n (%) 
Age (years) 
Male, n (%) 
Diabetes, n (%) 
Hypertension, n (%) 
Current Smoker, n (%) 
TG (mmol/L) 
TC (mmol/L) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
ApoA1 (g/L) 
ApoB (g/L) 
ApoE (mg/L) 
Lp(a) (mg/L) 
NTproBNP (ng/L) 
CRP (mg/L) 
hs-cTnT (ng/L) 8 (5-13) 205 (30-883)§§§ 162 (74-624)∆∆∆ 8 (5-11) 49 (9-263) ### 
STEMI vs. non-ACS: §p<0.05, §§p<0.01, §§§p<0.001. NSTEMI vs. non-ACS: ∆p<0.05, ∆∆p<0.01, ∆∆∆p<0.001 
UA vs. non-ACS: *p<0.05, **p<0.01, ***p<0.001. NSTE-ACS vs. non-ACS, #p<0.05 ##p<0.01, ###p<0.001 
ACS, acute coronary syndrome; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; NSTE-ACS, non-ST-
elevation acute coronary syndrome.
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Supplementary Table 3 Ceramides levels of included patients.   
STEMI vs. non-ACS: §p<0.05, §§p<0.01, §§§p<0.001. NSTEMI vs. non-ACS: ∆p<0.05, ∆∆p<0.01, ∆∆∆p<0.001 
UA vs. non-ACS: *p<0.05, **p<0.01, ***p<0.001. NSTE-ACS vs. non-ACS, #p<0.05 ##p<0.01, ###p<0.001  
ACS, acute coronary syndrome; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; NSTE-ACS, non-ST-
elevation acute coronary syndrome.
Parameters Non-ACS STEMI NSTEMI UA NSTE-ACS 
Cer(d18:1/16:0) 0.198 (0.162-0.241) 0.243 (0.206-0.282)§§§ 0.228 (0.200-0.286)∆∆∆ 0.242 (0.203-0.285)*** 0.235 (0.201-0.286) ### 
Cer(d18:1/18:0) 0.049 (0.036-0.065) 0.069 (0.052-0.086)§§§ 0.064 (0.047-0.085)∆∆∆ 0.068 (0.052-0.080)*** 0.066 (0.050-0.083) ### 
Cer(d18:1/24:0) 2.053 (1.592-2.672) 2.134 (1.675-2.702) 2.152 (1.674-2.737) 2.218 (1.684-2.771) 2.183 (1.675-2.756) 
Cer(d18:1/24:1(15Z)) 0.569 (0.436-0.739) 0.706 (0.571-0.980)§§§ 0.669 (0.519-0.906)∆∆∆ 0.764 (0.593-1.061)*** 0.732 (0.552-0.950) ### 
Cer(d18:1/14:0) 0.003 (0.002-0.004) 0.003 (0.002-0.004)§ 0.003 (0.002-0.004)∆∆∆ 0.003 (0.003-0.004)*** 0.003 (0.002-0.004) ### 
Cer(d18:1/20:0) 0.051 (0.039-0.065) 0.065 (0.051-0.081)§§§ 0.061 (0.049-0.076)∆∆∆ 0.063 (0.054-0.082)*** 0.062 (0.052-0.078) ### 
Cer(d18:1/22:0) 0.375 (0.294-0.480) 0.417 (0.334-0.518) 0.403 (0.324-0.520)∆∆∆ 0.439 (0.350-0.594)*** 0.413 (0.340-0.550) ### 
Cer(d18:0/16:0) 0.010 (0.007-0.013) 0.010 (0.008-0.013) 0.011 (0.008-0.015)∆∆∆ 0.013 (0.010-0.017)*** 0.012 (0.009-0.016) ### 
Cer(d18:0/18:0) 0.005 (0.003-0.007) 0.007 (0.004-0.011)§§§ 0.007 (0.004-0.011)∆∆∆ 0.007 (0.005-0.011)*** 0.007 (0.004-0.011) ### 
Cer(d18:0/24:0) 0.060 (0.042-0.086) 0.063 (0.043-0.085) 0.066 (0.049-0.087)∆∆ 0.075 (0.055-0.104)** 0.071 (0.052-0.096) ## 
Cer(d18:0/24:1(15Z)) 0.028 (0.019-0.041) 0.037 (0.025-0.053)§§§ 0.039 (0.024-0.054)∆∆∆ 0.045 (0.032-0.065)*** 0.042 (0.028-0.06) ### 
Cer(d18:1/24:1) 0.258 (0.192-0.372) 0.277 (0.204-0.377) 0.300 (0.230-0.366)∆∆∆ 0.333 (0.228-0.413)** 0.313 (0.229-0.389) ### 
Cer(d18:1/16:0)/Cer(d18:1/24:0) 0.095 (0.079-0.114) 0.111 (0.091-0.132)§§§ 0.103 (0.088-0.131)∆∆∆ 0.109 (0.090-0.133)*** 0.107 (0.090-0.133) ### 
Cer(d18:1/18:0)/Cer(d18:1/24:0) 0.023 (0.018-0.031) 0.032 (0.023-0.040)§§§ 0.030 (0.023-0.040)∆∆∆ 0.031 (0.023-0.039)*** 0.031 (0.023-0.039) ### 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) 0.261 (0.211-0.345) 0.312 (0.253-0.414)§§§ 0.314 (0.234-0.411)∆∆∆ 0.353 (0.267-0.481)*** 0.327 (0.255-0.429) ### 
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Supplementary Table 4. Correlations of ceramides levels and ratios with demographics and conventional ACS biomarkers. 
Ceramides Age TG TC HDL-C LDL-C ApoA1 ApoB ApoE Lp(a) hs-cTnT NTproBNP CRP 
Cer(d18:1/16:0) 0.044 0.262 0.515 0.015 0.466 0.069 0.453 0.333 0.068 0.124 0.155 0.231 
Cer(d18:1/18:0) -0.021 0.305 0.331 -0.074 0.278 -0.006 0.318 0.268 0.077 0.108 0.121 0.228 
Cer(d18:1/24:0) -0.077 0.397 0.491 -0.063 0.414 0.066 0.459 0.363 0.002 -0.024 -0.059 0.109 
Cer(d18:1/24:1(15Z)) 0.012 0.268 0.347 -0.021 0.292 0.025 0.317 0.271 0.083 0.095 0.142 0.181 
Cer(d18:1/14:0) 0.009 0.166 0.428 0.168 0.362 0.208 0.328 0.271 0.007 -0.069 -0.008 0.082 
Cer(d18:1/20:0) -0.021 0.309 0.343 -0.048 0.277 0.021 0.312 0.264 0.080 0.095 0.114 0.174 
Cer(d18:1/22:0) -0.083 0.405 0.480 -0.070 0.401 0.076 0.478 0.394 0.013 -0.011 -0.015 0.128 
Cer(d18:0/16:0) 0.051 0.228 0.396 0.013 0.342 0.070 0.341 0.297 0.022 0.054 0.085 0.168 
Cer(d18:0/18:0) 0.011 0.245 0.275 -0.088 0.246 -0.019 0.274 0.236 0.027 0.106 0.093 0.231 
Cer(d18:0/24:0) -0.004 0.204 0.389 0.028 0.352 0.068 0.305 0.232 0.010 0.025 0.011 0.130 
Cer(d18:0/24:1(15Z)) 0.016 0.238 0.308 -0.033 0.271 0.023 0.281 0.244 0.046 0.091 0.102 0.195 
Cer(d18:1/24:1) 0.034 -0.088 0.257 0.164 0.270 0.106 0.210 0.092 0.053 0.051 0.093 0.061 
Cer(d18:1/16:0)/Cer(d18:1/24:0) 0.153 -0.240 -0.091 0.098 -0.044 -0.018 -0.114 -0.122 0.067 0.148 0.236 0.097 
Cer(d18:1/18:0)/Cer(d18:1/24:0) 0.049 -0.031 -0.077 -0.023 -0.065 -0.064 -0.061 -0.037 0.074 0.136 0.175 0.144 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) 0.078 -0.095 -0.103 0.022 -0.084 -0.050 -0.094 -0.063 0.090 0.120 0.190 0.086 
Data are r values between ceramides levels and ratios with demographic parameters and conventional ACS biomarkers. P<0.05 in bold. 
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, 
apolipoprotein B; ApoE, apolipoprotein E; LP(a), lipoprotein(a); NTproBNP, N-terminal pro-brain natriuretic peptide; CRP, C-reactive protein; hs-cTnT, high-sensitivity 
cardiac troponin T; Cer, ceramides. 
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Sample size 
Conventional sample size calculations based on the effect size and variation of data are 
generally not applicable for observational studies especially involving complex multivariate 
analyses. Instead, we use the concept of margin of error to give a general indication of the 
precision of our estimates. The margin of error for a particular statistic of interest is usually 
defined as the radius (or half the width) of the confidence interval for that statistic. A sample 
size of 2773 patients in our study will give a margin of error of 1.8%, at a 95% confidence level, 
which indicates a high level of accuracy in our results. 
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STARD 2015
AIM 
STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the 
completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative 
study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts 
submitted for publication. 
EXPLANATION
A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as having 
a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the 
future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a 
combination of these, or any other method for collecting information about the current health status of a patient.
The test whose accuracy is evaluated is called index test. A study can evaluate the accuracy of one or more index tests. 
Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index 
test results with those of the reference standard. The reference standard is the best available method for establishing the 
presence or absence of the target condition. An accuracy study can rely on one or more reference standards.
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the 
reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target 
condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative 
index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy 
statistics can be estimated, such as the positive and negative predictive values of the test. Confidence intervals around 
estimates of accuracy can then be calculated to quantify the statistical precision of the measurements.
If the index test results can take more than two values, categorization of test results as positive or negative requires a test 
positivity cut-off. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) 
curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The 
area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test. 
The intended use of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The 
clinical role of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, 
replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test. 
Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical 
tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was 
not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply. 
DEVELOPMENT
This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, 
researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would 
help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of 
conclusions and recommendations. The list represents an update of the first version, which was published in 2003. 
More information can be found on http://www.equator-network.org/reporting-guidelines/stard.
Page 36 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
1
The Effect of Combined Testing of Ceramides with High-sensitive Troponin T on the 
Detection of Acute Coronary Syndrome in Patients with Chest Pain in China ： a 
prospective observational study
Authors: Kang Yao1*, MD; Yanzhong Wang2*, PhD; Xuebo Liu3, MD; Cheng-Xing Shen4, MD; Wei 
Hu5, MD; Zhe Wang1; Runda Wu1, MD; Xianglin Tang1, MD; Aijun Sun1,6, MD; Yunzeng Zou1, MD; 
Juying Qian1, MD; Guangyu Wu7, MD, PhD; Xin Guo7, MD; Xiaoliang Cheng7, PhD; Junbo Ge1, MD
* Drs Yao and Wang contributed equally.
1. Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, 
Fudan University, Shanghai, China
2. School of Population Health and Environmental Sciences, King’s College London, London, UK
3. Department of Cardiology, Tongji Hospital, Tongji University, Shanghai, China
4. Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 
Shanghai, China
5. Department of Cardiology, Minhang Hospital, Fudan University, Shanghai, China
6. Institute of Biomedical Science, Fudan University, Shanghai, China 
7. Qlife Lab Co., Ltd., 700 Yishan Road, Shanghai Putian Information Industrial Park, Shanghai, 
China
Corresponding author:
Prof. Junbo Ge, MD, FACC, FESC 
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
Zhongshan Hospital, Fudan University
Page 37 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
2
180 Fenglin Road, Shanghai, China. Postcode: 200032
Tel: 0086 (0)21 64041990-2152; Fax: 0086 (0)21 64437078 
Email: ge.junbo2@zs-hospital.sh.cn
Word count: 3420 (The word count excludes the title page, abstract, tables, acknowledgements, 
contributions and references.)
Page 38 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
3
Abstract 
Objective Ceramides are associated with coronary plaque vulnerability. We aim to investigate the 
potential diagnostic value of ceramides for Acute Coronary Syndrome (ACS) in Chinese patients with 
chest pain.
Design Prospective observational survey.
Setting Shanghai, China, 2016-7.
Participants 2773 patients with chest pain from four hospitals in Shanghai, China between August 
2016 and October 2017.
Main outcome measures Performance of metabolites model in detection of ACS cases including ST-
elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and 
unstable angina (UA).  
Results – Plasma levels of 12 ceramides molecules and corresponding ratios were compared between 
patients diagnosed with ACS and those without. Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) ratio, 
Cer(d18:1/14:0) and Cer(d18:1/22:0) were independent predictors of ACS after adjustment of 
traditional risk factors and high sensitive-cTnT. Receiver operating characteristic curve (ROC) analysis 
showed a significant improvement in detecting ACS in the multi-variable model with ceramides as 
compared to that without [0.865 (0.840-0.889) vs. 0.808 (0.776-0.841), P < 0.001].
Conclusion – Distinct plasma ceramides are independent diagnostic predictors of ACS among patients 
with chest pain. Ceramides together with high-sensitive troponin and traditional factors showed great 
potential in identifying ACS among patients with chest pain.
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Article Summary
Strengths and limitations of this study
 This is the first study with systematic demonstration of plasma levels of 12 ceramide molecules in 
2773 Chinese patients with chest pain.
 Performance of ceramides levels in diagnosing acute coronary syndrome was assessed and 
validated in multi-center clinical studies.
 The time of ceramides level elevation after ACS occurrence cannot be assessed in the study design.
Acknowledgements: The authors thank Qlife lab for technical assistance.
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acquisition of samples (YK, LX, SC, HW, WZ, WR, TX, SA, ZY, QJ); analysis and interpretation of 
data (WY, WG, GX, CX); drafting first version of the manuscript (WG, WY); critical revision of the 
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Patient and Public Involvement
This study was conducted without patient and public involvement. The patients were not invited to 
comment on the study design and were not consulted to develop outcomes or interpret the results. 
Patients were not invited to contribute to the writing or editing of this document for readability or 
accuracy.
The study complies with the Declaration of Helsinki and was approved by the Ethics Committees of 
the participating clinical centers. Written informed consent was obtained from all participants. 
Participation was voluntary and could be terminated at any time. All data were used strictly 
confidentially and anonymously. There are no plans to disseminate the results of the research to study 
participants.
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1. Introduction 
Acute Coronary Syndrome (ACS), which includes both myocardial infarction (MI) and unstable angina 
(UA), is estimated to affect 1.4 million people in the United States, and 2.5 million people in China per 
year.1 2 However, patients with acute chest pain suggestive of ACS present with a heterogeneous array 
of conditions, including both non-ischaemic and ischemic chest pain.3 Only 17% of these are finally 
diagnosed as ACS caused by atherosclerotic and ischaemic heart disease.3
The likelihood of ACS in patients with chest pain is estimated via the entire clinical picture, including 
symptoms and physical examination findings, disease history, electrocardiogram (ECG) changes, and 
biomarkers results. Among biomarkers, cardiac troponins play a central role in establishing a diagnosis 
and stratifying risk. Troponins are more specific and sensitive than the traditional cardiac enzymes such 
as creatine kinase (CK), its isoenzyme MB (CK-MB), and myoglobin.4 However, there has been an 
increasing recognition of other biomarkers recently.5 Considerable effort has been made to improve the 
multi-biomarker based evaluation and management of ACS. Altered lipid metabolism associated with 
inflammation and oxidative stress initiate the pathological changes, including the formation of lipid-
laden foam cells and the necrotic lipid core of unstable plaque.6 7 As many lipid types are essential in 
atherogenesis, they should be used for ACS prediction.6
Ceramides are a family of lipid molecules that are found in high concentrations within cell membranes 
and play a key role in a variety of physiology functions including apoptosis, cell growth, cell adhesion 
and plasma membrane integrity maintenance.8 All tissues can synthesize ceramides de novo from 
saturated fats and sphingosine.9 However, lesional low density lipoprotein (LDL) is known to be rich 
in ceramide in the atherosclerotic plaque, and it contains 10- to 50-fold-higher content of ceramide 
when compared with plasma LDL.10 An arterial-wall sphingomyelinase (SMase) hydrolyzes the 
sphingomyelin (SM) of retained LDL.10 Plasma ceramide (d18:1/16:0), is associated with the fraction 
of necrotic core tissue and lipid core burden in coronary atherosclerosis.11 Inflammatory cytokine tumor 
necrosis factor alpha was shown to induce the production of ceramide in vascular endothelial cells,12 13 
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via the activation of SMase, accompanied by reactive oxygen species production.14 High content of 
oxidized LDL (ox-LDL) in the plaque is capable of activating precursors to matrix metallopeptidase 2, 
propagating the signalling of the ceramide pathway by activation of SMase.15 These findings suggest 
abnormal regulation of ceramides might be related to plaque instability and triggering of ACS.
Previous clinical research found that circulating ceramides are elevated in patients with hypertension,16 
obesity,17 18 and type 2 diabetes mellitus.18 Ceramides ratio levels such as Cer(d18:1/16:0) / 
Cer(d18:1/24:0) ratio, Cer(d18:1/18:0) / Cer(d18:1/24:0) ratio, and Cer(d18:1/24:1) / Cer(d18:1/24:0) 
ratio were proposed as useful biomarkers for cardiovascular death (CV death) prediction, as assessed 
by three independent coronary artery disease (CAD) cohorts.19
Although several studies have shown plasma levels of specific ceramide molecules are correlated with 
diagnosis of patients with cardiac events, no studies to date has evaluated the role of these ceramide 
molecules in detecting ACS from patients with chest pain. In this study, we aim to assess the value of 
ceramides in detection of ACS in patients with chest pain and whether a combination of ceramides and 
troponin could improve the diagnostic power.
2. Methods
2.1. Study design and participants
This is a prospective observational study involving four University affiliated hospitals in Shanghai, 
China. A total of 2990 patients with chest pain were consecutively recruited in chest pain outpatient 
during Monday to Friday between August 2016 and October 2017, and 2773 patients were finally 
admitted to wards of cardiology after pre-screening by the exclusion criteria. Sample size calculation is 
shown in Supplementary File. Patients were eligible if they were aged ≥18 and ≤ 80 years, presented 
with signs and symptoms of chest pain and agreed to participate in this study. The exclusion criteria 
were pregnant women; organ transplant patients; patients suffering from bleeding disorders; patients 
Page 43 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
8
with neoplasms with a life expectancy <1 year; chronic kidney disease (eGFR＜60 mL/min/1.73m2) 
and patients with a clear non-cardiac chest pain. A flow chart describing the inclusion and exclusion 
process is shown as Figure 1.  Full study protocol is provided upon request to the corresponding author.
The study complies with the Declaration of Helsinki and was approved by the Ethics Committee of 
Zhongshan Hospital, the Ethics Committee of Tongji Hospital, the Ethics Committee of Shanghai Jiao 
Tong University Affiliated Sixth People’s Hospital, and the Ethics Committee of Minhang Hospital. 
Written informed consent was obtained from all participants. 
2.2. Clinical and laboratory data
Clinical history, physical examination findings and blood tests including renal and liver functions, C-
reactive protein (CRP), D-dimer and high-sensitive cTnT (Roche) levels, ECG, coronary angiogram 
and echocardiogram findings were recorded in all patients. Troponin levels were measured by 
electrochemiluminescence method using high sensitive-cTnT assay (Roche Diagnostics) on Roche 
Cobas e601. The coefficient of variation in the hs-cTnT assay is ≤10% at the cut-off value of 13 ng/L. 
The 99 percentile upper reference limit of hs-cTnT assay is 14 ng/L. Besides, the assay also has a limit 
of blank of 3 ng/L and a limit of detection of 5 ng/L, and the analytical range is 3-10000 ng/L. Regular 
blood lipid tests were conducted using standard methods. Specifically, total cholesterol (TC) was 
measured by enzymatic cholesterol method using cholesterol oxidase/peroxidase aminophenazone 
(COD-PAP) reagent while total triglyceride (TG) was measured by Glycerol-3-Phosphate 
oxidase/peroxidase anti-peroxidase method (GPO-PAP) method. Low-density lipoprotein cholesterol 
(LDL-C) and high-density lipoprotein cholesterol (HDL-C) were measured by homogenous PEG 
modification enzyme method. Other blood biomedical assay of apolipoprotein (AI, AII, B, and E), 
lipoprotein (a), and lipoprotein-associated phospholipase were performed by immune transmission 
turbidity method. Performers of the above tests were blinded to the diagnosis of diseases. The detection 
limit, analytical range, and reference interval or decision limit are summarized in Supplementary Table 
1.
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2.3. Diagnosis of ACS
The diagnosis of ACS including UA, Non-ST segment elevation myocardial infarction (NSTEMI), and 
ST-segment elevation myocardial infarction (STEMI) was made by two independent cardiologists by 
reviewing all patients’ notes, including symptoms, 12-lead ECG, and blood tests results according to 
the 2014 American Heart Association /American College of Cardiology guidelines and international 
definition of myocardial infarction version 3. Type 1 and type 2 MI were both included.20 21 The 
agreement level and kappa value between the 2 cardiologists were 0.99 and 0.98. The cases where the 
2 cardiologists disagreed were reviewed by a senior cardiologist. All the cardiologists were blinded to 
ceramide levels. Cardiac chest pain with persistent ECG findings of elevation in the ST segment indicate 
STEMI. Cardiac chest pain and elevations in troponins levels without ST elevation indicate NSTEMI. 
Those with presence of 1 or more of 3 principal ischemic symptoms ((1) rest angina (lasting >20 
minutes), (2) new-onset (<2 months previously) severe angina, and (3) a crescendo pattern of 
occurrence (increasing in intensity, duration, frequency, or any combination of these factors)) without 
elevations in cardiac troponins are defined as UA.5 Participants were diagnosed with ACS when there 
is evidence of UA, NSTEMI or STEMI.
2.4. Quantification of plasma ceramides
Potential ceramides were generated from previous untargeted and targeted ceramide profile studies.22 23 
Analyses of 12 plasma ceramides were performed using a Waters Xevo TQ-S mass spectrometer 
(Manchester, UK) equipped with Waters Acuity UPLC I-Class (Milford, MA, USA) in a hospital and 
Qlife lab collaborative laboratory based in Department of Cardiology. The mass spectrometry was 
operated in multiple-reaction monitoring (MRM) mode with ESI-positive ionization. The capillary 
voltage was set at 3.0 kV. and the source temperature was 120℃. The desolvation temperature and gas 
flow were 400℃ and 800L/h, respectively. The source offset was maintained at 60V.
Page 45 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
10
Blood samples for ceramides test were collected and centrifuged using ethylene diamine tetraacetic acid 
(EDTA) anticoagulation tube at admission. Plasma were immediately stored in -80℃ for future 
analysis. Ceramides test were taken immediately after samples of all patients were collected.  Before 
analysis, the samples were thawed at room temperature, then a volume of 800 μl of protein precipitation 
solution (isopropanol) that containing D7-Cer d18:1/16:0 (0.01 pmol/μl), D7-Cer d18:1/18:0 (0.005 
pmol/μl), D7-Cer d18:1/24:0 (0.015 pmol/μl) and D7-Cer d18:1/24:1 (0.015 pmol/μl) was pipetted into 
1.5 mL Eppendorff tube after addition of 50 μL of plasma sample. The mixture was thoroughly vortexed 
for 10 min followed by 5-min centrifugation at 14,000 rpm. Supernatant (70 μL) was collected for 
LC/MS/MS analysis. Ceramides ratios were calculated using Cer(d18:1/16:0), Cer(d18:1/18:0), 
Cer(d18:1/24:1(15Z)) and Cer(d18:1/24:0).23 Lab technicians who were in charge for ceramides test 
were blinded to disease diagnosis.
2.5. Statistical methods
Continuous variables are summarized as mean (standard deviation) or median (interquartile range) and 
categorical data as count (percentage). Student’s t-test, Mann-Whitney U, and Wilcoxon signed rank 
tests were used to test differences in continuous variables where appropriate, and Chi-squared test was 
used for proportions. Univariate logistic regression was used to analyse the association of each variable 
and binary outcome. Multivariable logistic regression analyses were undertaken to identify the 
demographic, clinical and laboratory factors associated with ACS in patients with chest pain after 
adjusting for potential confounders and the final models included variables significantly associated with 
ACS.
Training and validation cohorts were developed via a 10-fold cross-validation approach repeated 10 
times.24 The estimate of prediction error is almost unbiased under 10-fold cross-validation. Repeated 
10 times that minimizes the cross-validated error is then used to build the final model.25 26 The 
performance and discrimination ability of the five models were assessed using the area under the 
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receiver operating curve (AUROC) and net reclassification index (NRI). ROC curves and NRI values 
were compared among models in training and validation datasets. 
All tests were two-tailed, and P values less than 0.05 were considered statistically significant. Odds 
ratios (OR) with 95% confidence intervals (CIs) for the chosen clinical and laboratory variables in the 
logistic regression models and AUROC and NRI values with 95% CIs for different test datasets were 
calculated. Statistical analyses were done with statistical software R, version 3.4.3.
2.6.Patient and Public Involvement
This study was conducted without patient and public involvement. 
3. Results
3.1. Demographics, lipid profiles and laboratory findings of patients 
The demographics, clinical and lab findings of all participants are reported in Table 1. Serial troponin 
levels were measured at 0h-3h after admission in all recruited patients and all patients underwent 
echocardiography and coronary angiography. In 2773 patients with chest pain, 354 (12.8%) were 
diagnosed with ACS, among whom 116 (4.2%) were UA, 114 (4.1%) were NSTEMI, and 124 (4.5%) 
were STEMI. All 116 patients with UA had a significant stenosis on coronary angiography. Compared 
to those without ACS, patients with ACS are more likely to be men (73.44% vs 67.57%), to be current 
smokers (31.35% vs 21.62%), and to have hypertension (68.92% vs 62.00%). Lipid profiles and 
lipoproteins including TG, TC, LDL-C, ApoB, ApoE, Lipoprotein(a) (Lp(a)) were significantly 
elevated in patients diagnosed with ACS while HDL-C and apolipoprotein A1 (ApoA1) were 
significantly lower in ACS patients (all p<0.001, except for Lp(a), p=0.023). CRP and cardiac damage 
markers including hs-cTnT and N-terminal pro-brain natriuretic peptide (NTproBNP) levels were 
significantly higher in ACS patients (all p<0.001). Demographics, lipid profiles and laboratory findings 
of patients diagnosed with STEMI, NSTEMI and UA were also reported in Supplementary Table 2.
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3.2. Plasma ceramides levels in ACS patients
Table 2 presents the levels of twelve ceramides molecules in patients with and without ACS. The levels 
of 12 ceramide molecules (Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:0), Cer(d18:1/24:1(15Z)), 
Cer(d18:1/14:0), Cer(d18:1/20:0), Cer(d18:1/22:0), Cer(d18:0/16:0), Cer(d18:0/18:0), Cer(d18:0/24:0), 
Cer(d18:0/24:1(15Z)), Cer(d18:1/24:1)) were all significantly elevated in patients with ACS compared 
to those without (all p<0.001, except for Cer(d18:1/24:0), p=0.028) (Table 2). In addition, 3 ceramide 
ratios (Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0)) were also significantly increased in ACS patients with all p 
values less than 0.001. In patients diagnosed with UA and NSTEMI, levels of ceramides and ceramide 
ratios were also significantly high r compared to patients diagnosed with non-ACS (Supplementary 
Table 3).
3.3. Association between plasma ceramides and traditional and cardiac damage markers 
The associations between plasma ceramides with traditional ACS risk factors and cardiac markers for 
myocardial injury are shown in Supplementary Table 4. Most of the 12 ceramide molecules and 
ceramide ratios were moderately correlated with lipid profiles including TG, TC, LDL-C, ApoB and 
ApoE, while CRP was shown to be weakly correlated with ceramides. There was no significant 
correlation between ceramides and myocardial damage markers including hs-cTnT and NTproBNP. 
3.4. Clinical predictors and multi-variable models for ACS
Clinical predictors for ACS were identified in univariate logistic regression analysis and are shown in 
Table 3. Being male, having hypertension, and being current smoker were significantly associated with 
ACS (p<0.05). Besides, most of the lipid profile (TG, TC, HDL-C, LDL-C, ApoA1 and ApoB) were 
significantly associated with ACS (all p<0.001). Also, increased levels of hs-cTnT (OR and 95%CI: 
2.45 [2.23-2.70]), NTproBNP (1.73 [1.60-1.87]) and CRP (1.73 [1.58, 1.90]) were significantly 
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associated with ACS. Furthermore, all 12 ceramides levels and 3 ceramides ratios were significantly 
associated with ACS with all p<0.001 except Cer(d18:1/24:0) with p=0.025 (Table 3).
Multivariable logistic regression analyzing independently significant predictors of ACS are shown in 
Table 4. Model 1 included traditional risk factors such as hypertension, current smoker, CRP, LDL-C 
and NTproBNP (all p<0.001 except for hypertension p=0.033). Model 2 only included hs-cTnT (2.454 
[2.239-2.701], p<0.001). Model 3 included traditional risk factors and hs-cTnT. Current smoker, CRP, 
LDL-C, NTproBNP as well as hs-cTnT were independently significant in detecting patients with ACS. 
Model 4 included traditional risk factors and ceramides levels, with OR (95%CI) of 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0): 2.960 (2.156-4.072), Cer(d18:1/14:0): 1.439 (1.007-2.062) and 
Cer(d18:1/22:0): 2.079 (1.315-3.288). Model 5 included traditional risk factors, hs-cTnT (2.190, 
[1.939-2.485]) and ceramides levels (Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0): 4.455 [3.112-6.396], 
Cer(d18:1/14:0): 1.73 [1.166-2.605], and Cer(d18:1/22:0): 2.301 [1.371, 3.866], all p<0.01). Ceramides 
were shown to be independently associated with ACS after adjusting for traditional factors and hs-
cTnT.
3.5. Discrimination and reclassification of ACS with various multi-variable logistic regression 
models
As shown in Table 5, the model including traditional factors (hypertension, current smoker, LDL-C, 
CRP and NT-proBNP level) had an area under the curve (AUC) of 0.780 (0.750-0.811) in diagnosing 
ACS. AUC of hs-cTnT in predicting ACS was 0.800 (0.767-0.833). After combining traditional factors 
and hs-cTnT, the AUC became 0.808 (0.776-0.841) (Figure 2A). The AUC of model including 
traditional factors and ceramides was 0.811 (0.784-0.837). Notably, when combining traditional factors, 
hs-cTnT, and ceramides, the AUC of the model rose to 0.865 (0.840-0.889) (Figure 2B). We also 
compared discrimination and reclassification power of these models. Results showed that ceramides 
significantly improved the AUC of the model with traditional factors and hs-cTnT (0.865 [0.840-0.889] 
vs. 0.808[0.776-0.841], p<0.001). Net reclassification index (NRI) analyses also showed that the model 
Page 49 of 61
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
14
including traditional factors and hs-cTnT was significantly improved by the inclusion of ceramides 
(NRI=0.511 (0.388-0.635), p<0.001).
4. Discussion 
In this study of 2773 Chinese patients with chest pain from four hospitals in Shanghai, China, levels of 
12 ceramides were systematically evaluated together with that of traditional risk factors and high-
sensitive troponin. Ceramides and their ratios were shown to be independent predictors of ACS in 
patients with chest pain after adjustment for traditional risk factors (e.g., age, sex, body mass index 
(BMI), smoking status, and blood cholesterol) and cardiac damage biomarkers (i.e., high-sensitive 
troponin). The proposed model with ceramides showed substantial promise and improved value as a 
risk evaluation tool for ACS with improved performance on model discrimination and reclassification. 
With targeted liquid chromatography–mass spectrometry based lipidomic approach, we have 
successfully established the characteristics of cardiac risk-related ceramides from 2773 Chinese patients 
with chest pain and confirmed our hypothesis that plasma levels of ceramide subspecies correlate with 
atherosclerotic plaque instability and hence might be used as lipidomic markers for ACS. 
This is to our knowledge the first study with systematic demonstration of plasma levels of 12 ceramide 
molecules in a Chinese population. Also, the selection of two ceramides molecules and one ceramide 
ratio as potential biomarkers for ACS has not been reported before. Although our ceramides-based 
diagnostic model showed great potential in identifying ACS among patients with chest pain, its clinical 
utility especially regarding rule-in and rule-out strategies and performances still need to be further 
investigated and validated to make it fully applicable in clinical settings. We were also restricted for 
not measuring ceramides levels in a serial pattern and lacking information about the relationships 
between ceramides levels and time from the onset of ACS. The study was possibly also limited by a 
potential selection bias for patients with higher risk of ACS during recruitment process from admitted 
patients rather than patients in emergency departments. In addition, the results found in our study need 
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to be validated in independent external cohorts. An improvement in the test technique of ceramides, 
including standardization of test protocol and automated pretreatment of samples is also needed to fulfil 
the requirement of clinical practice.
Our findings of two ceramides molecules (Cer(d18:1/14:0), Cer(d18:1/22:0)) and one ceramide ratios 
(Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0)) as diagnostic biomarkers for ACS among patients with 
suspected symptoms have never been reported before. In addition, only relatively modest correlations 
between ceramides and lipid profiles including TG, TC, LDL-C, ApoB and ApoE were detected and 
there was no significant correlation between ceramides with hs-cTnT, NT-proBNP and CRP levels, 
suggesting that the diagnostic value of ceramides for ACS might be independent of the above laboratory 
variables. Moreover, AUROC of multi-variable models showed significant improvement of ceramides 
on traditional risk factors and high-sensitive troponin T. This result provides evidence that distinct 
ceramide species serve as independent predictors for the risk of ACS, in addition to conventional blood 
biomarkers such as HDL-C and CRP levels. Ceramides measurement in high-throughput quality-
controlled environments is straightforward.19 By setting up clinical laboratories equipped with robotized 
sample handling systems and mass spectrometry equipment, it would be feasible to identify patients 
with chest pain at high cardiovascular risk using our ceramides-based diagnostic model. 19
Previous clinical research found that elevated ceramide plasma concentrations are associated with 
coronary plaque vulnerability evaluated by intravascular ultrasound virtual histology and near-infrared 
spectroscopy.11 Untargeted lipidomic analyses have identified CAD risk-related ceramide molecules 
(Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1)) and their ratios with Cer(d18:1/24:0) as potential 
risk stratifiers for CAD patients.22 A previous study applying ceramides to the prediction of 
cardiovascular death from patients with CAD showed that ceramides, independent of other lipid 
markers and CRP, were significantly associated with CV death.19 In a recent study including 495 
participants with coronary angiography and followed up for 18 years, ceramides were not associated 
with CAD but were independently associated with major adverse cardiovascular events.23 A weighted 
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sum of ceramides including Cer22:0 and Cer24:1 was also reported to be associated with a 2.18-fold 
higher risk of cardiovascular disease, which was similar with our results.27 Recent studies showed 
targeted profiling of ceramides predicted short-term and long-term major adverse cardiac events 
(MACE).28 29 Moreover, a consistent increase in ceramide levels and overexpression of 3 enzymes in 
ceramide biosynthesis were found on rat ischemic myocardium, which is consistent with the elevated 
plasma levels of ceramides found in our cohort.29 Nevertheless, no study has identified the diagnostic 
value of ceramides in patients with chest pain, while we develop models with lipidomic markers for 
ACS with additional value upon conventional factors and troponin.
Currently, the standard process for the diagnostic assessment of ACS in patients with suspected 
symptoms relies on clinical evaluation and high-sensitive troponin tests.4 20 However, high-sensitive 
troponin assays identify a larger number of patients with elevated troponin results but without a final 
diagnosis of ACS, making interpretation of test results challenging.30 The adoption of highly sensitive 
assays for ACS detection should be accompanied by serial tests and implementation of algorithms, 
leading to a longer period of observation31. In the current settings of Chinese hospitals, self-paying 
patients with chest pain tend to be over-prescribed by cardiologists with invasive and expensive tests 
such as coronary angiography. Noteworthily, ceramides levels of patients with UA are higher than those 
without ACS, which indicates that ceramides may help in identifying patients with UA and higher risk 
of ACS from populations without significant elevation of cardiac troponins. Moreover, ceramides levels 
were higher in NSTEMI patients compared to non-ACS ones, indicating a possible role of ceramides in 
distinguishing between patients with elevated troponins caused by ACS or non-ACS conditions. 
Nevertheless, the potential roles of ceramides in clinical diagnosis of UA and NSTEMI need further 
independent investigation and validation.
In conclusion, we have identified ceramides as independent biomarkers associated with ACS and 
developed a ceramides-based model to evaluate ACS risk among patients with chest pain. The model 
showed good model discrimination and net reclassification improvement as compared to other models. 
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Our study characterises ceramides species in Chinese patients with chest pain and demonstrates that 
ceramides are of diagnostic value and have the potential for detecting ACS, in addition to currently used 
lipid markers and high-sensitive troponin. 
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Table 1. Demographics, clinical and lab findings of included patients in total cohort.
Variables Total cohort (n=2773) non-ACS (n=2419) ACS (n=354) P
Age (years) 63.5 (9.6) 63.4 (9.4) 63.8 (10.6) 0.515
Male, n (%) 1894 (68.3) 1634 (67.6) 260 (73.4) 0.031
Diabetes, n (%) 689 (24.8) 600 (24.8) 89 (25.1) 0.943
Hypertension, n (%) 1744 (62.9) 1500 (62.0) 244 (68.9) 0.014
Current Smoker, n (%) 634 (22.9) 523 (21.6) 111 (31.4) <0.001
TG (mmol/L) 1.46 (1.03-2.10) 1.43 (1.01-2.07) 1.61 (1.16-2.23) <0.001
TC (mmol/L) 3.78 (3.17-4.59) 3.74 (3.13-4.49) 4.28 (3.51-5.01) <0.001
HDL-C (mmol/L) 1.09 (0.90-1.30) 1.09 (0.91-1.31) 1.01 (0.88-1.23) <0.001
LDL-C (mmol/L) 1.93 (1.40-2.61) 1.88 (1.36-2.53) 2.42 (1.77-3.08) <0.001
ApoA1 (g/L) 1.32 (1.16-1.51) 1.33 (1.17-1.52) 1.24 (1.08-1.43) <0.001
ApoB (g/L) 0.73 (0.58-0.91) 0.72 (0.57-0.89) 0.84 (0.67-1.03) <0.001
ApoE (mg/L) 38.0 (30.0-47.0) 37.0 (30.0-46.4) 41.0 (32.0-51.0) <0.001
Lp(a) (mg/L) 125.0 (53.0-290.3) 123.0 (51.0-282.0) 152.0 (65.0-329.0) 0.023
NTproBNP 
(ngpg/Lml) 100.0 (44.7-268.1) 87.4 (42.3-220.3) 364.1 (113.4-1264.0) <0.001
CRP (mg/L) 1.7 (0.7-5.5) 1.5 (0.6-4.8) 5.4 (1.8-13.9) <0.001
hs-cTnT (ng/L) 9 (5-16) 8 (5-13) 71 (11-474) <0.001
Data are median (interquartile range) or count (percentage). 
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; 
ApoB, apolipoprotein B; ApoE, apolipoprotein E; LP(a), lipoprotein(a); NTproBNP, N-terminal pro-brain natriuretic peptide; CRP, C-reactive protein; hs-
cTnT, high-sensitivity cardiac troponin T.
P value for the difference between patients diagnosed as ACS and non-ACS. 
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Table 2. Plasma levels of ceramides molecules and ratios in total cohort and by ACS status.
Ceramides (μmol/L) Total cohort (n=2773) non-ACS (n=2419) ACS (n=354) P
Cer(d18:1/16:0) 0.203 (0.165-0.248) 0.198 (0.162-0.241) 0.237 (0.203-0.286) <0.001
Cer(d18:1/18:0) 0.051 (0.037-0.069) 0.049 (0.036-0.065) 0.068 (0.051-0.084) <0.001
Cer(d18:1/24:0) 2.065 (1.607-2.680) 2.053 (1.592-2.672) 2.164 (1.675-2.757) 0.028
Cer(d18:1/24:1(15Z)) 0.583 (0.448-0.767) 0.569 (0.436-0.739) 0.730 (0.557-0.950) <0.001
Cer(d18:1/14:0) 0.0027 (0.0020-0.0036) 0.0027(0.0020-0.0035) 0.0030 (0.0024-0.0040) <0.001
Cer(d18:1/20:0) 0.053 (0.040-0.067) 0.051 (0.039-0.065) 0.063 (0.051-0.078) <0.001
Cer(d18:1/22:0) 0.381 (0.300-0.490) 0.375 (0.294-0.480) 0.416 (0.336-0.540) <0.001
Cer(d18:0/16:0) 0.010 (0.007-0.014) 0.010 (0.007-0.013) 0.011 (0.008-0.015) <0.001
Cer(d18:0/18:0) 0.005 (0.003-0.008) 0.005 (0.003-0.007) 0.007 (0.004-0.011) <0.001
Cer(d18:0/24:0) 0.061 (0.042-0.086) 0.060 (0.042-0.086) 0.068 (0.048-0.094) <0.001
Cer(d18:0/24:1(15Z)) 0.029 (0.020-0.044) 0.028 (0.019-0.041) 0.040 (0.026-0.058) <0.001
Cer(d18:1/24:1) 0.262 (0.195-0.375) 0.258 (0.192-0.372) 0.298 (0.221-0.386) <0.001
Ceramides Ratio
Cer(d18:1/16:0)/Cer(d18:1/24:0) 0.096 (0.080-0.116) 0.095 (0.079-0.114) 0.107 (0.090-0.132) <0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0) 0.024 (0.019-0.032) 0.023 (0.018-0.031) 0.031 (0.023-0.039) <0.001
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) 0.269 (0.214-0.360) 0.261 (0.211-0.345) 0.321 (0.253-0.426) <0.001
Data are median (interquartile range). 
P value for the difference between patients diagnosed as ACS and non-ACS. 
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Table 3. Univariate logistic regression showing significant predictors of ACS in patients 
with chest pain.
Total Cohort (n=2773)
Variables
OR (95%CI) P
Age 1.00 (0.99-1.02) 0.476
Gender 1.33 (1.04-1.71) 0.027
Diabetes 1.02 (0.78-1.31) 0.890
Hypertension 1.36 (1.07-1.73) 0.012
Current Smoker 1.66 (1.29-2.11) <0.001
TG* 1.40 (1.15-1.70) <0.001
TC* 5.17 (3.30-8.15) <0.001
HDL-C* 0.44 (0.30-0.66) <0.001
LDL-C* 3.14 (2.37-4.17) <0.001
ApoA1* 0.17 (0.09-0.29) <0.001
ApoB* 2.83 (2.05-4.01) <0.001
ApoE* 0.93 (0.76-1.17) 0.534
Lp(a)* 1.10 (1.00-1.21) 0.055
NTproBNP* 1.73 (1.61-1.88) <0.001
CRP* 1.74 (1.59-1.90) <0.001
hs-cTnT* 2.45 (2.24-2.70) <0.001
Cer(d18:1/16:0)* 7.53 (5.11-11.17) <0.001
Cer(d18:1/18:0)* 4.67 (3.55-6.17) <0.001
Cer(d18:1/24:0)* 1.41 (1.05-1.90) 0.025
Cer(d18:1/24:1(15Z))* 5.09 (3.79-6.87) <0.001
Cer(d18:1/14:0)* 2.04 (1.59-2.62) <0.001
Cer(d18:1/20:0)* 4.55 (3.35-6.22) <0.001
Cer(d18:1/22:0)* 2.36 (1.75-3.18) <0.001
Cer(d18:0/16:0)* 2.02 (1.61-2.55) <0.001
Cer(d18:0/18:0)* 2.26 (1.92-2.66) <0.001
Cer(d18:0/24:0)* 1.49 (1.21-1.84) <0.001
Cer(d18:0/24:1(15Z))* 2.73 (2.24-3.33) <0.001
Cer(d18:1/24:1)* 1.57 (1.26-1.96) <0.001
Cer(d18:1/16:0)/Cer(d18:1/24:0)* 4.11 (2.87-5.89) <0.001
Cer(d18:1/18:0)/Cer(d18:1/24:0)* 3.84 (2.93-5.05) <0.001
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0)* 2.63 (2.08-3.34) <0.001
Data are odds ratio (OR) (95%CI). *Log transformed before analysis.
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoE, 
apolipoprotein E; LP(a), lipoprotein(a); NTproBNP, N-terminal pro-brain natriuretic peptide; CRP, C-
reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; Cer, ceramides.
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Table 4. Multivariable logistic regression showing significant predictors of ACS in patients with chest pain after adjustment for conventional risk 
factors.  
Baseline variables Model 1 Model 2 Model 3 Model 4 Model 5
Hypertension 1.37 (1.03-1.83)* — 1.35 (0.98-1.87) 1.41 (1.06-1.90)* 1.40 (1.01-1.96)*
Current Smoker 1.93 (1.43-2.58)‡ — 1.52 (1.09-2.10)* 1.99 (1.47-2.69)‡ 1.58 (1.12-2.21)†
LDL-C§ 2.63 (1.91-3.64)‡ — 2.01 (1.42-2.87)‡ 2.13 (1.51-3.04)‡ 1.64 (1.12-2.41)*
CRP§ 1.40 (1.27-1.55)‡ — 1.20 (1.07-1.34)† 1.38 (1.25-1.53)‡ 1.16 (1.03-1.31)*
NTproBNP§ 1.63 (1.49-1.78)‡ — 1.16 (1.04-1.29)† 1.57 (1.44-1.72)‡ 1.07 (0.95-1.19)
hs-cTnT§ — 2.45 (2.24-2.70)‡ 2.02 (1.80-2.27)‡ — 2.19 (1.94-2.49)‡
Cer(d18:1/24:1(15Z))/Cer(d18:1/
24:0)§ — — — 2.96 (2.16-4.07)‡ 4.46 (3.11-6.40)‡
Cer(d18:1/14:0)§ — — — 1.44 (1.01-2.06)* 1.74 (1.17-2.61)†
Cer(d18:1/22:0)§ — — — 2.08 (1.32-3.29)† 2.30 (1.37-3.87)†
Data are odds ratio (OR) (95%CI). §Log transformed before analysis.
Model 1. Included traditional risk factors (Hypertension, current smoker, LDL-C, CRP and NTproBNP levels).
Model 2. Only Included hs-cTnT.
Model 3. Included traditional risk factors, and hs-cTnT.
Model 4. Included traditional risk factors, and ceramides.
Model 5. Included traditional risk factors, hs-cTnT and ceramides.
LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; NTproBNP, N-terminal pro-brain natriuretic peptide; hs-cTnT, high-sensitivity cardiac 
troponin T; Cer, ceramides.
* P<0.05.
† P<0.01.
‡ P<0.001. 
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Table 5. Discrimination and reclassification of ACS with various multivariable logistic regression models. 
*Traditional risk factors include hypertension, current smoker, LDL-C, CRP and NTproBNP levels. 
†Ceramides include Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0), Cer(d18:1/14:0) and Cer(d18:1/22:0).
LDL-C, CRP, NT-proBNP, hs-cTnT and ceramides levels are log transformed before analysis.
hs-cTnT, high-sensitivity cardiac troponin T; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; NT-proBNP, N-terminal pro-brain 
natriuretic peptide.
P values-AUC and P values-NRI are for the difference between old models and new models. Bold used to highlight those P values<0.05.
Old model New model AUC (95% CI) P Value-AUC NRI (95% CI) P Value-NRI
Traditional factors* - 0.78 (0.75-0.81) - - -
hs-cTnT - 0.80 (0.77-0.83) - - -
Traditional factors* +hs-cTnT 0.81 (0.78-0.84) 0.220 0.52 (0.40-0.64) <0.001
Traditional factors* +Ceramides† 0.81 (0.78-0.84) <0.001 0.35 (0.23-0.47) <0.001
Traditional factors* + hs-cTnT +Ceramides† 0.87 (0.84-0.89) <0.001 0.51 (0.39-0.64) <0.001
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Figure 1: Flow chart.
Figure 2: Receiver operating characteristic (ROC) curves of multi-variable models for the 
discrimination of ACS.
(A) Traditional risk factors (hypertension, current smoker, LDL-C, CRP and NT-proBNP) and high-sensitive 
troponin are included in the model. (B) Traditional risk factors (hypertension, current smoker, LDL-C, CRP 
and NT-proBNP), high-sensitive troponin, Cer(d18:1/14:0), Cer(d18:1/22:0) and 
Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) are included in the model.
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